SANA vs. RARE

Last updated Jun 4, 2026

SANA (Sana Biotechnology, Inc.) and RARE (Ultragenyx Pharmaceutical Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, SANA returned -31.74%/yr vs -24.64%/yr for RARE. At a 0.41 correlation, their price movements are largely independent.

Performance

SANA vs. RARE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SANA achieves a -23.34% return, which is significantly lower than RARE's -2.57% return.

SANA

• 1D: -3.70%
• 1M: -8.50%
• YTD: -23.34%
• 6M: -30.20%
• 1Y: 33.33%
• 3Y*: -21.42%
• 5Y*: -31.74%
• 10Y*: —

RARE

• 1D: 2.89%
• 1M: -9.67%
• YTD: -2.57%
• 6M: -38.52%
• 1Y: -38.43%
• 3Y*: -23.90%
• 5Y*: -24.64%
• 10Y*: -10.71%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SANA vs. RARE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SANA Sana Biotechnology, Inc.	-23.34%	149.69%	-60.05%	3.29%	-74.48%	-55.90%
RARE Ultragenyx Pharmaceutical Inc.	-2.57%	-45.33%	-12.02%	3.22%	-44.90%	-45.75%

Correlation

The correlation between SANA and RARE is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.33
Correlation (3Y) Calculated over the trailing 3-year period	0.34
Correlation (5Y) Calculated over the trailing 5-year period	0.41
Correlation (All Time) Calculated using the full available price history since Feb 5, 2021	0.41

Fundamentals

Market Cap SANA : $863.79M RARE : $2.25B
EPS SANA : -$0.94 RARE : -$6.11
Total Revenue (TTM) SANA : $0.00 RARE : $669.43M
Gross Profit (TTM) SANA : $0.00 RARE : $559.44M
EBITDA (TTM) SANA : -$193.23M RARE : -$522.35M

Return for Risk

SANA vs. RARE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SANA

SANA Risk / Return Rank: 55
SANA Sharpe Ratio Rank: 53
SANA Sortino Ratio Rank: 59
SANA Omega Ratio Rank: 57
SANA Calmar Ratio Rank: 55
SANA Martin Ratio Rank: 52

RARE

RARE Risk / Return Rank: 18
RARE Sharpe Ratio Rank: 17
RARE Sortino Ratio Rank: 22
RARE Omega Ratio Rank: 20
RARE Calmar Ratio Rank: 15
RARE Martin Ratio Rank: 16

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SANA vs. RARE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SANA	RARE	Difference
Sharpe ratio: Return per unit of total volatility	0.35	-0.55	+0.90
Sortino ratio: Return per unit of downside risk	1.24	-0.34	+1.59
Omega ratio: Gain probability vs. loss probability	1.15	0.94	+0.21
Calmar ratio: Return relative to maximum drawdown	0.61	-0.70	+1.31
Martin ratio: Return relative to average drawdown	1.04	-1.14	+2.18
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SANA vs. RARE - Sharpe Ratio Comparison

The current SANA Sharpe Ratio is 0.35, which is higher than the RARE Sharpe Ratio of -0.55. The chart below compares the historical Sharpe Ratios of SANA and RARE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	SANA	RARE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.35	-0.55	+0.90
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.27	-0.46	+0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.31	-0.09	-0.23

Drawdowns

SANA vs. RARE - Drawdown Comparison

The maximum SANA drawdown since its inception was -96.92%, which is greater than RARE's maximum drawdown of -89.57%. Use the drawdown chart below to compare losses from any high point for SANA and RARE.

Drawdown Indicators

	SANA	RARE	Difference
Max Drawdown Largest peak-to-trough decline	-96.92%	-89.57%	-7.35%
Max Drawdown (1Y) Largest decline over 1 year	-54.73%	-55.36%	+0.63%
Max Drawdown (3Y) Largest decline over 3 years	-88.11%	-68.83%	-19.28%
Max Drawdown (5Y) Largest decline over 5 years	-94.82%	-82.02%	-12.80%
Max Drawdown (10Y) Largest decline over 10 years	—	-89.57%	—
Current Drawdown Current decline from peak	-92.83%	-87.37%	-5.46%
Average Drawdown Average peak-to-trough decline	-81.47%	-54.74%	-26.73%
Ulcer Index Depth and duration of drawdowns from previous peaks	32.14%	33.85%	-1.71%

Volatility

SANA vs. RARE - Volatility Comparison

Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE) have volatilities of 14.31% and 13.85%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SANA	RARE	Difference
Volatility (1M) Calculated over the trailing 1-month period	14.31%	13.85%	+0.46%
Volatility (6M) Calculated over the trailing 6-month period	52.42%	67.49%	-15.07%
Volatility (1Y) Calculated over the trailing 1-year period	95.88%	69.92%	+25.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	118.43%	53.96%	+64.47%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	117.26%	55.34%	+61.92%

Dividends

SANA vs. RARE - Dividend Comparison

Neither SANA nor RARE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both SANA and RARE in my portfolio?

SANA and RARE have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SANA or RARE?

SANA has higher volatility (14.31%) compared to RARE (13.85%). In terms of maximum drawdown, SANA dropped -96.92% vs RARE's -89.57%.

Which has better risk-adjusted returns?

SANA currently has the higher Sharpe Ratio (0.35 vs -0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.